Efalizumab, a monoclonal antibody targeting CD11a, which, together with CD18, constitutes a crucial part of lymphocyte LFA-1, inhibits the assembly of the IS by modulating the activation of T cells through integrin signaling,465 has achieved success in clinical trials for treating patients with moderate to severe psoriasis.466. Here, ITGAL is linked to psoriasis.